<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="9db609da-42a0-42b1-87f5-020261a871ad"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use CEQUA safely and effectively.  See full prescribing information for CEQUA.<br/>
      <br/>CEQUA<sup>®</sup> (cyclosporine ophthalmic solution) 0.09%, for topical ophthalmic use<br/>Initial U.S. Approval: 1983</title>
   <effectiveTime value="20250306"/>
   <setId root="48c3d8a3-4289-4b52-9189-58b48596095c"/>
   <versionNumber value="12"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="146974886" root="1.3.6.1.4.1.519.1"/>
            <name>Sun Pharmaceutical Industries, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="146974886" root="1.3.6.1.4.1.519.1"/>
                  <name>Sun Pharmaceutical Industries, Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="574139809" root="1.3.6.1.4.1.519.1"/>
                        <name>Laboratoire Unither</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47335-506" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47335-507" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="984004661" root="1.3.6.1.4.1.519.1"/>
                        <name>Teva Czech Industries s.r.o</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="api manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47335-506" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="api manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="47335-507" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2ea89fe7-f83e-4343-8385-64907eb79f0a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250122"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="47335-506" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>CEQUA</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>cyclosporine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="0.0009"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="83HN0GTJ6D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYCLOSPORINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="83HN0GTJ6D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CYCLOSPORINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="0.01"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7YC686GQ8F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYOXYL 40 HYDROGENATED CASTOR OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="0.0005"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9T1C662FKS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OCTOXYNOL-40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="0.0053"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5QWK665956" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="0.0047"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="22ADO53M6F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="0.0005"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="0.003"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="RDH86HJV5Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K90</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.25"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43215" displayName="VIAL, SINGLE-DOSE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <formCode code="C43200" displayName="POUCH" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="6"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="47335-506-96" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43178" displayName="BOX" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20180815"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value codeSystem="2.16.840.1.113883.3.26.1.1" code="C102842" displayName="Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210913" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20180815"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180815"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="47335-507" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>CEQUA</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>cyclosporine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.0009"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="83HN0GTJ6D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYCLOSPORINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="83HN0GTJ6D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CYCLOSPORINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="0.01"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7YC686GQ8F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYOXYL 40 HYDROGENATED CASTOR OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="0.0005"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9T1C662FKS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OCTOXYNOL-40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="0.0053"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5QWK665956" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="0.0047"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="22ADO53M6F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="0.0005"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="g" value="0.003"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="RDH86HJV5Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K90</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.25"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43215" displayName="VIAL, SINGLE-DOSE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <formCode code="C43200" displayName="POUCH" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="47335-507-97" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43178" displayName="BOX" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20180815"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value codeSystem="2.16.840.1.113883.3.26.1.1" code="C102842" displayName="Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210913" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20180815"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180815"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="fde671ae-9117-438c-9184-be1a3ac7516a"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>CEQUA ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye). (<linkHtml href="#S1">1</linkHtml>)</paragraph>
               </text>
               <effectiveTime value="20210326"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>CEQUA ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye) (<linkHtml href="#S1">1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="1c55b11d-6533-493e-8b2d-c930ff3071fd"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <text>
                  <paragraph>Instill one drop of CEQUA twice daily (approximately 12 hours apart) into each eye. CEQUA can be used concomitantly with artificial tears, allowing a 15 minute interval between products. Discard the vial immediately after using in both eyes. (<content styleCode="underline">
                        <linkHtml href="#S2">2</linkHtml>
                     </content>)</paragraph>
               </text>
               <effectiveTime value="20220715"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Instill one drop of CEQUA twice daily (approximately 12 hours apart) into each eye. Discard the vial immediately after using in both eyes (<content styleCode="underline">
                              <linkHtml href="#S2">2</linkHtml>
                           </content>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="8fde20e8-0f27-42ec-b7a8-d0bcddbd604b"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Ophthalmic solution containing cyclosporine 0.9 mg/mL (<linkHtml href="#S3">3</linkHtml>)</paragraph>
               </text>
               <effectiveTime value="20210326"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic solution containing cyclosporine 0.9 mg/mL (<linkHtml href="#S3">3</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="05214ada-7d5d-49bb-b7f1-225b0f45bfab"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>None. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
               </text>
               <effectiveTime value="20210326"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#S4">4</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="9f0eebc0-fe4f-4d1c-b97e-ea6b198071e7"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20210326"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces (<linkHtml href="#S5.1">5.1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="539df020-9316-4845-bb0b-3505d9c759c7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Potential for Eye Injury and Contamination </title>
                     <text>
                        <paragraph>To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.</paragraph>
                     </text>
                     <effectiveTime value="20210326"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="d8ce9502-0e96-48ec-bcb0-53598117611f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Use with Contact Lenses </title>
                     <text>
                        <paragraph>CEQUA should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of CEQUA ophthalmic solution.</paragraph>
                     </text>
                     <effectiveTime value="20210326"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="46fea9b3-56e3-4be4-b651-f6598770b360"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <effectiveTime value="20210326"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions following the use of CEQUA (cyclosporine ophthalmic solution) 0.09% was instillation site pain (22%) and conjunctival hyperemia (6%) (<linkHtml href="#S6.1">6.1</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold">
                              <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="2fee8ac4-c775-4397-ac8c-5f55a00c05d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>In clinical trials, 769 subjects received at least 1 dose of cyclosporine ophthalmic solution. The majority of the treated subjects were female (83%). The most common adverse reactions reported in greater than 5% of subjects were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other adverse reactions reported in 1% to 5% of the patients were blepharitis, eye irritation, headache, and urinary tract infection.</paragraph>
                     </text>
                     <effectiveTime value="20210326"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="60a07e8f-837e-4c55-9f7c-702291751ea8"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20210326"/>
               <component>
                  <section ID="S8.1">
                     <id root="44e0bc43-3da4-4f04-a777-5321fa232a28"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>There are no adequate and well-controlled studies of CEQUA administration in pregnant women to inform a drug-associated risk. Oral administration of cyclosporine to pregnant rats or rabbits did not produce teratogenicity at clinically relevant doses [see Data].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Oral administration of cyclosporine oral solution (USP) to pregnant rats or rabbits was teratogenic at maternally toxic doses of 30 mg/kg/day in rats and 100 mg/kg/day in rabbits, as indicated by increased pre- and postnatal mortality, reduced fetal weight and skeletal retardations. These doses (normalized to body weight) were approximately 3200 and 21000 times higher than the maximum recommended human ophthalmic dose (MRHOD) of 1.5 mcg/kg/day, respectively. No adverse embryofetal effects were observed in rats or rabbits receiving cyclosporine during organogenesis at oral doses up to 17 mg/kg/day or 30 mg/kg/day, respectively (approximately 1800 and 6400 times higher than the MRHOD, respectively).</paragraph>
                        <paragraph>An oral dose of 45 mg/kg/day cyclosporine (approximately 4800 times higher than MRHOD) administered to rats from Day 15 of pregnancy until Day 21 postpartum produced maternal toxicity and an increase in postnatal mortality in offspring. No adverse effects in dams or offspring were observed at oral doses up to 15 mg/kg/day (approximately 1600 times greater than the MRHOD).</paragraph>
                     </text>
                     <effectiveTime value="20210326"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="7cab85cd-3f71-4942-970c-08d1e7247331"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Cyclosporine blood concentrations are low following topical ocular administration of CEQUA <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#S12.3">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. There is no information regarding the presence of cyclosporine in human milk following topical administration or on the effects of CEQUA on the breastfed infants and milk production. Administration of oral cyclosporine to rats during lactation did not produce adverse effects in offspring at clinically relevant doses <content styleCode="italics">[see Pregnancy (</content>
                           <content styleCode="italics">
                              <linkHtml href="#S8.1">8.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CEQUA and any potential adverse effects on the breast-fed child from cyclosporine.</paragraph>
                     </text>
                     <effectiveTime value="20210326"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="32f118c3-7d13-4161-8b22-ae6660093a36"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and efficacy of CEQUA ophthalmic solution have not been established in pediatric patients below the age of 18.</paragraph>
                     </text>
                     <effectiveTime value="20210326"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="5a805a9e-7d66-488f-9101-abeadf1cfd76"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20210326"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="6af53ded-09fb-4f66-ae0c-d4a8482badb8"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>CEQUA (cyclosporine ophthalmic solution) 0.09% contains a topical calcineurin inhibitor immunosuppressant. Cyclosporine’s chemical name is Cyclo[[(E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl] and it has the following structure:</paragraph>
                  <paragraph>Structural Formula</paragraph>
                  <renderMultiMedia referencedObject="MM101"/>
                  <paragraph>Formula: C<sub>62</sub>H<sub>111</sub>N<sub>11</sub>O<sub>12</sub> Mol. Wt.: 1202.6</paragraph>
                  <paragraph>Cyclosporine is a white powder that is insoluble in water. CEQUA is supplied as a sterile, clear, colorless ophthalmic solution for topical ophthalmic use. It has an osmolality of 160 to 190 mOsmol/kg and a pH of 6.5-7.2. Each mL of CEQUA contains: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Active: cyclosporine 0.09%</item>
                     <item>Inactives: Polyoxyl 40 Hydrogenated Castor Oil, Octoxynol-40, polyvinylpyrrolidone, sodium phosphate monobasic dihydrate, sodium phosphate dibasic anhydrous, sodium chloride, water for injection, and sodium hydroxide or hydrochloric acid to adjust pH.</item>
                  </list>
               </text>
               <effectiveTime value="20220715"/>
               <component>
                  <observationMedia ID="MM101">
                     <text>structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="e1496fc3-6422-493f-95cd-27d89f90cfe5"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20210326"/>
               <component>
                  <section ID="S12.1">
                     <id root="2f791b64-0531-49fe-90f8-28f6783c373a"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Cyclosporine is a calcineurin inhibitor immunosuppressant agent when administered systemically. In patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, topical administration of cyclosporine is thought to act as a partial immunomodulator. The exact mechanism of action is not known.</paragraph>
                     </text>
                     <effectiveTime value="20210326"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="355e7478-59f6-4680-8666-daa54c745054"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Blood concentrations of cyclosporine after twice daily topical ocular administration of CEQUA into each eye of healthy subjects for up to 7 days, and once on Day 8, were either not detectable or were marginally above the lower limit of assay quantitation of 0.100 ng/mL (range 0.101 to 0.195 ng/mL) for up to 2 hours after a single dose, and up to 4 hours after multiple doses.</paragraph>
                     </text>
                     <effectiveTime value="20210326"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="fb7d5229-67c9-4ae8-8cfa-5ad1198829b7"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20220715"/>
               <component>
                  <section ID="S13.1">
                     <id root="a50b255e-7bc3-4a57-a665-ab1d309e7177"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis </content>
                        </paragraph>
                        <paragraph>Systemic carcinogenicity studies were carried out in male and female mice and rats. In the 78-week oral (diet) mouse study, at doses of 1, 4, and 16 mg/kg/day, evidence of a statistically significant trend was found for lymphocytic lymphomas in females, and the incidence of hepatocellular carcinomas in mid-dose males significantly exceeded the control value. </paragraph>
                        <paragraph>In the 24-month oral (diet) rat study, conducted at 0.5, 2, and 8 mg/kg/day, pancreatic islet cell adenomas significantly exceeded the control rate in the low dose level. The hepatocellular carcinomas and pancreatic islet cell adenomas were not dose related. The low doses in mice and rats are approximately 55 times higher than the maximum recommended human ophthalmic dose (1.5 mcg/kg/day), normalized to body surface area.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>In genetic toxicity tests, cyclosporine has not been found to be mutagenic/genotoxic in the Ames Test, the V79-HGPRT Test, the micronucleus test in mice and Chinese hamsters, the chromosome-aberration tests in Chinese hamster bone-marrow, the mouse dominant lethal assay, and the DNA-repair test in sperm from treated mice. Cyclosporine was positive in an in vitro sister chromatid exchange (SCE) assay using human lymphocytes.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Oral administration of cyclosporine to rats for 12 weeks (male) and 2 weeks (female) prior to mating produced no adverse effects on fertility at doses up to 15 mg/kg/day (1620 times higher than the maximum recommended human ophthalmic dose).</paragraph>
                     </text>
                     <effectiveTime value="20220715"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="a6519337-167b-4088-92c2-d4db66bb0747"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>Two multicenter, randomized, adequate and well-controlled clinical studies treated 1,048 patients with keratoconjunctivitis sicca (NCT # 02254265 and NCT # 02688556). In both studies, compared to vehicle at Day 84, there was a statistically significant (p&lt;0.01) higher percentage of eyes with increases of ≥ 10 mm from baseline in Schirmer wetting. This effect was seen in approximately 17% of CEQUA-treated patients versus approximately 9% of vehicle-treated patients.</paragraph>
                  <table width="100%">
                     <col width="20%" align="left" valign="middle"/>
                     <col width="20%" align="left" valign="middle"/>
                     <col width="20%" align="left" valign="middle"/>
                     <col width="20%" align="left" valign="middle"/>
                     <col width="20%" align="left" valign="middle"/>
                     <thead>
                        <tr>
                           <td colspan="5" align="center">
                              <paragraph>
                                 <content styleCode="bold">Tear Production</content>
                              </paragraph>
                           </td>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Lrule">
                              <paragraph> </paragraph>
                           </td>
                           <td colspan="2" styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>
                                 <content styleCode="bold">OTX-101-2014-001</content>
                              </paragraph>
                           </td>
                           <td colspan="2" styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>
                                 <content styleCode="bold">OTX-101-2016-001</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule"/>
                           <td styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>
                                 <content styleCode="bold">CEQUA</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">N=152</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>
                                 <content styleCode="bold">Vehicle</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">N=152</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>
                                 <content styleCode="bold">CEQUA</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">N=371</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>
                                 <content styleCode="bold">Vehicle</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">N=373</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule">
                              <paragraph>≥ 10-mm increase in tear production</paragraph>
                              <paragraph>(% of eyes) at Day 84 </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>16.8%</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>8.6%</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>16.6%</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>9.2%</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule">
                              <paragraph>Difference (95% CI)</paragraph>
                           </td>
                           <td colspan="2" styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>8.2% (1.9%, 14.6%)</paragraph>
                           </td>
                           <td colspan="2" styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>7.3% (3.3%, 11.3%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule">
                              <paragraph>p-value versus vehicle </paragraph>
                           </td>
                           <td colspan="2" styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>&lt;0.01</paragraph>
                           </td>
                           <td colspan="2" styleCode="Rrule Lrule Botrule" align="center">
                              <paragraph>&lt;0.01</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph> </paragraph>
               </text>
               <effectiveTime value="20220715"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="74f7b72e-20a4-4643-acae-657f4ec6eef9"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>CEQUA ophthalmic solution is packaged in sterile, preservative-free, single-use vials. Each vial</paragraph>
                  <paragraph>contains 0.25 mL fill in a 0.9 mL LDPE vial; 10 vials (2 cards of 5 vials) are packaged in a</paragraph>
                  <paragraph>polyfoil aluminum pouch; 6 pouches are packaged in a box. The entire contents of each box of</paragraph>
                  <paragraph>60 vials must be dispensed intact.</paragraph>
                  <paragraph>60 Single-Use Vials 0.25 mL each - NDC 47335-506-96</paragraph>
                  <paragraph>Storage: Store at 20°C to 25°C (68°F to 77°F). Store single-use vials in the original foil pouch.</paragraph>
               </text>
               <effectiveTime value="20210326"/>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="a8543322-b3c3-4cb1-9491-df04d98f1501"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Handling the Vial</content>
                  </paragraph>
                  <paragraph>Advise patients to not allow the tip of the vial to touch the eye or any surface, as this may</paragraph>
                  <paragraph>contaminate the solution. Advise patients also not to touch the vial tip to their eye to avoid the</paragraph>
                  <paragraph>potential for injury to the eye <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#S5.1">5.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Use with Contact Lenses</content>
                  </paragraph>
                  <paragraph>CEQUA should not be administered while wearing contact lenses. Patients with decreased tear</paragraph>
                  <paragraph>production typically should not wear contact lenses. Advise patients that if contact lenses are</paragraph>
                  <paragraph>worn, they should be removed prior to the administration of the solution. Lenses may be</paragraph>
                  <paragraph>reinserted 15 minutes following administration of CEQUA ophthalmic solution <content styleCode="italics">[see Warnings</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#S5.2">5.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Administration</content>
                  </paragraph>
                  <paragraph>Advise patients that the solution from one individual single-use vial is to be used immediately</paragraph>
                  <paragraph>after opening for administration to one or both eyes, and the remaining contents should be</paragraph>
                  <paragraph>discarded immediately after administration.</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Manufactured for: Sun Pharmaceutical Industries Limited</paragraph>
                  <paragraph>By: Laboratoire Unither</paragraph>
                  <paragraph>1 rue de l’Arquerie</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>50200 Coutances</paragraph>
                  <paragraph>France</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Cyclosporine (active ingred.) Product of Czech Republic.</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Product of France</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>Sun Pharmaceutical Industries, Inc.</paragraph>
                  <paragraph>Cranbury, NJ 08512</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Copyright 2022, Sun Pharmaceutical Industries Limited</paragraph>
                  <paragraph>All rights reserved</paragraph>
                  <paragraph>07/2022</paragraph>
                  <paragraph>uspi-CEQUA-sol-00004</paragraph>
               </text>
               <effectiveTime value="20220715"/>
            </section>
         </component>
         <component>
            <section ID="SPSPK">
               <id root="b923719d-a741-4202-b418-3ec5eadc666b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 47355-506-96</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For topical use in the eye</content>
                     <br/>
                     <content styleCode="bold">sterile, Preservative-Free</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cequa</content>
                     <sup>®</sup>
                     <br/>
                     <content styleCode="bold">(cyclosporine ophthalmic solution) 0.09%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">60 SINGLE-USE VIALS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">6 pouches x 10 single-use vials (0.25 mL each)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep out of reach of children.</content>
                     <br/>
                     <content styleCode="bold">Not child resistant.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SUN PHARMA</content>
                  </paragraph>
                  <paragraph> </paragraph>
                  <renderMultiMedia referencedObject="MM102"/>
               </text>
               <effectiveTime value="20220715"/>
               <component>
                  <observationMedia ID="MM102">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="Image.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="SPSPJ">
               <id root="8b9ae1cb-0348-406f-bf67-3012e01d3be8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 47355-507-97</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For topical use in the eye</content>
                     <br/>
                     <content styleCode="bold">sterile, Preservative-Free</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cequa</content>
                     <sup>®</sup>
                     <br/>
                     <content styleCode="bold">(cyclosporine ophthalmic solution) 0.09%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">10 SINGLE-USE SAMPLE VIALS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 pouches x 10 single-use vials (0.25 mL each)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep out of reach of children.</content>
                     <br/>
                     <content styleCode="bold">Not child resistant.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SUN PHARMA</content>
                  </paragraph>
                  <paragraph> </paragraph>
                  <renderMultiMedia referencedObject="MM103"/>
               </text>
               <effectiveTime value="20220715"/>
               <component>
                  <observationMedia ID="MM103">
                     <text>image1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>